Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study.
European Journal of Cancer(2019)
摘要
•The regorafenib toxicity profile was similar to that in the phase III trials in metastatic colorectal cancer.•Nearly half of the patients started regorafenib at a dose of <160 mg daily.•Results for median overall survival and progression-free survival were similar to those reported in the phase III trials.
更多查看译文
关键词
Regorafenib,Survival analysis,Observational study,Adverse effects
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要